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The effectiveness of anti-retroviral therapies (ART) depends on its ultimate ability to clear reservoirs of continuous human immunodeficiency
virus (HIV) infection. We reasoned that a principal vehicle for viral dissemination, the mononuclear phagocytes could also serve as an ART
transporter and as such improve therapeutic indices. A nanoparticle–indinavir (NP–IDV) formulation was made and taken up into and released
from vacuoles of human monocyte-derived macrophages (MDM). Following a single NP–IDV dose, drug levels within and outside MDM
remained constant for 6 days without cytotoxicity. Administration of NP–IDV when compared to equal drug levels of free soluble IDV
significantly blocked induction of multinucleated giant cells, production of reverse transcriptase activity in culture fluids and cell-associated HIV-
1p24 antigens after HIV-1 infection. These data provide “proof of concept” for the use of macrophage-based NP delivery systems for human
HIV-1 infections.
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The inability to eradicate human immunodeficiency virus
(HIV) reservoirs coupled with the increasingly common
emergence of drug-resistant viral strains has focused attention
on developing improved anti-retroviral therapy (ART) delivery
systems (Ayre, 1989; Michaelis et al., 2000; Rowe et al., 2005).⁎ Corresponding author. Department of Pharmacology and Experimental
Neuroscience, 985880 Nebraska Medical Center Omaha, NE 68198-5880,
USA. Fax: +1 402 559 3744.
E-mail address: hegendel@unmc.edu (H.E. Gendelman).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.08.012If achieved, ART effectiveness in combating reservoirs of
persistent infection could be significantly improved (Chen et al.,
2002; Chulamokha et al., 2005; Delaugerre et al., 2005b). As
viral mutations that impact resistance emerge following the
selective pressure of drug treatment, improvements in the
pharmacokinetics and drug delivery of ART could positively
affect therapeutic endpoints (Chen et al., 2002; Murri et al.,
2006; Shehu-Xhilaga et al., 2005). Moreover, viral fitness,
defined by HIV's ability to replicate in a defined environment is
aided by ART limitations (De Rossi, 2004). An example occurs
in viral sanctuaries, such as the central nervous system, where
ART entry is impeded by the limitations in anti-retroviral drug
Fig. 1. NP–IDV morphology analyzed by SEM and AFM. SEM (magnification
×12,000) showed spherical and smooth surfaces of NP with sizes of
approximately 1.6 μm (A). The AFM tapping mode images of NP–IDV
showed 2×2 μm of planar image (B) and 800×600×16 nm of three-
dimensional image (C).
149H. Dou et al. / Virology 358 (2007) 148–158passage through the blood brain barrier (Aweeka et al., 1999;
Thomas, 2004) . Back mutation of virus from brain to blood can
also perpetuate such events (Koblet, 1998; Marshall, 1988; Smit
et al., 2004). In order to address this issue, we reasoned that
drug carriage and subsequent tissue distribution into sites of
active viral replication would be enhanced, in significant
measure, if drugs were transported within the same cells serving
as vehicles for viral-tissue dissemination. Previous reports in
both laboratory and animal systems investigated a key
candidate, the mononuclear phagocyte (MP; monocytes, tissue
macrophages and dendritic cells) as potential drug transporters
(Basu and Lala, 2004; Liu et al., 1998; Monkkonen et al., 1993;
Rossi et al., 1998). These studies investigated anti-retroviral
properties of anti-retroviral drugs packaged in divergent carrier
systems, however key pharmacokinetics for drug usage and a
proven efficacy over soluble free drug was not realized.
Moreover, as MPs are the principal cells infected early in the
course of viral infection, serve as reservoirs for continued viral
replication, act as vehicles for viral spread to CD4+ T
lymphocytes, and are disease inducers in brain and lung
where viral infection and immune activation of MP are linked to
tissue injury (Collman et al., 2003; Gendelman et al., 1994;
Kadiu et al., 2005; Kim et al., 2005; Maslin et al., 2005; Meltzer
and Gendelman, 1988; Persidsky and Gendelman, 2003), drug-
induced cytotoxicity needed to be investigated. All together,
despite ART efficacy, it is compromised by its inherent
physicochemical properties and limitations in bio-distribution
and cellular uptake (Swindells, 2005). These observations
support a need for the development of improved ART drug
delivery systems.
In an attempt to realize this goal, we developed a MP-based
ART carrier system using nanoparticles (NP). We theorized that
such a system could be capable of overcoming pharmacologic
barriers, thus enabling improved therapeutic outcomes. In
support of this idea were previous successes of such systems for
treatment of cancer and microbial infections and HIV-1
infection (Aliautdin et al., 2003; Berton et al., 2001; Chan,
2006; Feng et al., 2004; Jain, 2005a, 2005b; Leroux et al., 1995;
Pandey et al., 2005). In the current report, NP–indinavir (NP–
IDV) was packaged into monocyte-derived macrophages
(MDM). IDV was chosen for “proof of concept” as it is a
potent HIV-1 protease inhibitor and is a common component of
ART regimens (Perno et al., 1998; Prejdova et al., 2004). NP–
IDV was readily taken up and released by MDM and showed
sustained and potent anti-retroviral activities. The anti-retroviral
activities were superior from what was observed for the IDV
free form (soluble drug). These observations hold significant
promise for improving tissue drug distribution and dosing
regimens in infected people.
Results
NP–IDV characters
The final mean NP size of the suspension was 1.6 μm, with
99% of the particles (by volume) less than 8.4 μm. The process
was optimized for temperature, pressure and homogenizationcycles. Scanning electron microscopy (SEM) and atomic force
microscopy (AFM) were employed to visualize NP morphol-
ogy. SEM demonstrated homogeneous size distributions of NP
crystal structures (Fig. 1A). AFM tapping mode images of the
NP–IDV showed planar and three-dimensional NP images with
spherical and crystal architecture. The scan ranges were
2×2 μm and 800×600×16 nm, and demonstrated spherical
150 H. Dou et al. / Virology 358 (2007) 148–158NP shapes (Figs. 1B and C) with similar widths and heights of
the individual particles. NP revealed a relatively smooth surface
and suggested that a drug release mechanism could involve
diffusion through the material matrix, channels, and pores. The
flattened NP–IDV morphology reflected its deposition on
cleaved mica plates (Chen et al., 2006; Shahgaldian et al.,
2002).
NP–IDV cellular localization
Images of Lissamine rhodamine B 1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine, triethylammonium salt
(rDHPE) labeled NP–IDV containing cells show concentra-
tion-dependent signal intensity (red color) after NP–IDV 12 h
of NP–IDV exposure (Fig. 2). The MDM readily phagocytized
the NP–IDV. More than 95% of MDM were rDHPE–NP–IDV
positive after 12 h of incubation. The confocal Z scan
demonstrated that rDHPE–NP–IDV (red) was evenly distrib-
uted throughout the MDM (Figs. 2A–I). rDHPE–NP–IDV
were located inside the cells and the fluorescence signal were
located in cytoplasmic vacuoles.
NP–IDV uptake and cytotoxicity measurements
NP–IDV uptake by MDM over a 12 h time period was
evaluated by fluorescence microscopy and RP-HPLC analysis.
The fluorescence images demonstrate that rDHPE–NP–IDV is
taken up by MDM over time. The fluorescence signal showedFig. 2. Cytoplasmic localization of rDHPE–NP–IDV. The Z scan results showed that
fluorescent dye accumulated within the cytoplasm.that rDHPE–NP–IDV entered MDM within 10 min of
incubation (Fig. 3A). At 2 h, 50% of MDM contained NP–
IDV, increased to 95% by 8 h constant to 12 h. Although NP
uptake is known to be dependent on particle size (Dailey et
al., 2003; Griese and Reinhardt, 1998; Singh et al., 2003),
particle size distribution of NP–IDV did not influence uptake
by MDM. A stereo-selective RP-HPLC method was used to
measure intracellular drug concentrations. Without media ex-
change, the intracellular levels of IDV were 9.5±0.8, 8.8±0.3,
5.3±0.2 and 5.9±0.5 mM/3×107 cells at days 1, 3, 5, and 7,
respectively. Seventy-four percent of IDV was present inside
cells at day 1 decreasing to 39% by day 7. HPLC tests
confirmed MDM NP–IDV uptake by morphological examina-
tions (Figs. 3A and B). RP-HPLC measurements of IDV
levels over time are illustrated in Fig. 3B. MTT-based cell
viability assays showed that MDM treated with NP–IDV or
free IDV at concentrations ranging from 10− 6 to 10− 15 M
showed no significant change in viability after 7 days of NP–
IDV administration (Fig. 3C). Although the initial drug
concentration used was 5×10− 4 M the amount actually
taken by the MDM was within the range of the MTT assay
and demonstrated no evident cell toxicities.
NP–IDV release
Alkaline pH minimizes solubility, thus enhancing the
physical stability of NP–IDV (Jin et al., 2006; Zhang et al.,
2006). Following phagocytosis, decreasing pH withinthe cytoplasm appeared red after NP uptake (A–I). Ingested NP appeared as red
Fig. 3. NP–IDV uptake. rDHPE–NP–IDV uptake in MDMwas analyzed for 8 h (A). Fluorescence microscopy showed NP (red) uptake into MDM. HPLC quantified
IDV levels from lysates of MDM sampled (B). MDM viability was tested by the mitochondrial MTT assay following exposure of free and IDV nanosuspensions at
concentrations of 10− 6 to 10− 15 M. No changes in MTT levels were observed amongst all groups tested (C).
151H. Dou et al. / Virology 358 (2007) 148–158phagosomes leads to increased solubility and release of drug
into the surrounding cytoplasm. Two very distinct physico-
chemical steps are involved in the release of intracellular NP–
IDV and include the initial dissolution of the NP in the cell and
subsequent diffusion of the released IDV into the extracellular
media. We used fluorescent microscopy to assess rDHPE–NP–
IDV release after a single washout (Fig. 4A). The release profile
of IDV from NP–IDV loaded MDM was evaluated by RP-
HPLC with measurements taken during the initial 24 h after a
single washout and daily thereafter. An initial burst-release
effect of IDV was shown at 2 h post-washout into the
extracellular space (media) at 37% of initial intracellular IDV
levels. Without medium changes, relatively consistent intracel-
lular IDV levels were observed over 3 days (Fig. 4B). In
comparison to results illustrated in Fig. 4B, the intracellular
levels of NP–IDV were rapidly decreased after 24 h following
daily washout (Fig. 4C). These results also revealed that media
exchanges affected the plateau of the dissolution curve.
Moreover, NP–IDV release from MDM into the extracellular
milieu was affected more by serial media exchanges than by
time. The levels of intracellular IDV were reduced following
each exchange (Fig. 4C).NP–IDV inhibits HIV-1-induced cytopathicity and progeny
virion production
To determine the antiviral activities of NP–IDV loaded
MDM, cytopathology was evaluated between control (uninfect-
ed) and HIV-1 infected MDM including treated with or without
NP–IDV. HIV-1 infected MDM induced typical cytopathicity
and notably the formation of multinucleated giant cells (MGC)
by day 5 post-infection (Fig. 5A). MDM treated with NP–IDV
showed NP uptake (darkened MDM cytoplasmic vacuoles),
while cytopathicity and MGC formation were abrogated.
Transmission electron microscopic (TEM) images confirmed
light microscopy results in that progeny virions were seen in
cytoplasmic vesicles of HIV-1 infected MDM (Fig. 5B), but not
in NP–IDV-treated HIV-1 infected cells (Fig. 5C). The results
demonstrate that NP–IDV treatment attenuated progeny virion
production in infected MDM.
Comparative anti-retroviral activities of solution and NP–IDV
We compared the duration of anti-retroviral efficacy of in
vitro treatment with NP–IDVand soluble IDV sulfate to inhibit
Fig. 4. NP–IDV release. rDHPE–NP–IDV release was measured from MDM over a 5 day observation period (A). The density of rDHPE–NP–IDV (red) was
sustained for 4 days (A). After single washout, extracellular (media) and intracellular (MDM) IDV levels, were assayed by HPLC (B). With subsequent daily media
changes, intracellular and extracellular levels of IDV progressively diminished until reaching a nadir at day 5, when IDV levels fell below the limit of detection (C).
Drug concentrations were reduced, as no new drug was added to the macrophages.
152 H. Dou et al. / Virology 358 (2007) 148–158progeny virion production in HIV-1ADA infected MDM. All
treated cells shown in Fig. 6Awere HIV-1 infected. MDM were
pre-treated with NP–IDV, itraconazole NP, or soluble IDV
sulfate for 5 days and then exposed to virus. HIV-1 infected
MDM that were treated with nanosuspensions without IDV or
remained untreated served as positive HIV-1 infection controls.
Levels of viral replication were determined by RT activity (Fig.
6A). Significant inhibition of RT activity at all tested times was
observed in HIV-1 infectedMDM treated with either IDV sulfate
solution or NP–IDV-compared to each positive HIV-1 infection
control. However, treatment with NP–IDV showed significantly
limited RT activities to backgroud on days 3, 5, and 7 (P<0.03,
P<0.01, and P<0.01, respectively) compared to soluble IDV
sulfate drug treatment increasing viral replication level parallel
post-infection time. Treatment with NP lacking IDV showed no
anti-retroviral activities compared to untreated controls. HIV-
1p24 expression in soluble IDV sulfate or NP–IDV treated HIV-
1 infectedMDMwas tested by immunohistological examination
at day 7 post-infection. Fluorescent microscopy showed a large
proportion of multinucleated (blue) HIV-1 p24 positive (red)
MDM in HIV-1 positive control cultures, whereas NP–IDV-treated cultures showed limited numbers of infected cells (Fig.
6B). Soluble IDV sulfate reduced the numbers of HIV-1 p24
positive cells, but that reduction was remarkably limited
compared to the virtual elimination of HIV-1 p24 observed in
MDM treated with NP–IDV. To examine the effect of NP–IDV
and soluble IDV sulfate on cell viability during infection, cell
viability of HIV-1 infected MDM on days 3, 5, and 7 post-
infection were analyzed by MTT assay. None of the drug
formulations induced significantly detectable loss of cell
viability as determined, whereas HIV-1 infected MDM showed
progressive loss of cell viability over time resulting in a
significant reduction in cell viability by day 7 after viral infec-
tion. Interestingly, cell viabilities were increased at day 7 with
itraconazole NP. Although there is no simple explanation for this
observation the changes may reflect ongoing phagocytosis and
its effects on intracellular signaling events linked to cell death.
Discussion
In recent years, the use of NP as a carrier system for cell
specific targeting and delivery of drugs has gained an increasing
Fig. 5. Morphological features of HIV-1-infected MDM following NP–IDV treatment. HIV-1 infected MDM cells exposed to NP–IDV appeared dark due to
cytoplasmic uptake of NP (A). Virus-induced cytopathicity was abrogated after NP–IDV. The treated cells showed similar morphology to uninfected controls at all
time points compared to infected and untreated cells. MGC were observed at days 5 and 7 in HIV-1 infected MDMwithout NP–IDV treatment. Original magnification
×200. TEM demonstrated uptake of NP–IDV into MDM and vesicles without progeny viral particles (B). Untreated HIV-1 infected MDM showed classic
cytopathology including MGC formation and viral particles inside cytoplasmic vesicles (C). Original magnification ×20,000.
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Karlsen, 2002). Relevant to the current study, we now
demonstrate that an anti-retroviral drug, such as IDV, can be
manufactured into NP, rapidly loaded into macrophages, and
subsequently afford significant anti-retroviral activities (includ-
ing inhibition of MGC formation, progeny virion production
and intracellular p24 antigen expression), without untoward
cytotoxicity, for periods measured in days. Sustained drug
release from macrophage was observed for at least 5 days. Thekey to the successful uptake and release of NP–IDV revolves, in
part, around the size and charge, which enters the macrophage at
robust levels, despite the lipophilic nature of the cellular plasma
membranes. The immediate goal for any drug delivery vehicle
is to promote maximal cell uptake and release with minimal
cytotoxicity. Moreover, such a drug formulation obviates the
need for large amounts of orally administered drugs that are
now required to maintain pharmacologically active concentra-
tions in HIV-1 target tissues (Dou et al., in press).
Fig. 6. Anti-retroviral activities of NP–IDV. A single dose of soluble IDV sulfate
or NP–IDV was administered to MDM 5 days before HIV-1ADA challenge. The
MDM were then analyzed at days 3, 5 and 7 post-infection. An intraconazole
loaded NP was used as a control. RT activity was used to assay progeny virion
production 7 days after viral exposure in all experimental groups (A). Both
treated cultures showed a significant prevention of viral replication as compared
to untreated HIV-1 infected MDM (*P<0.05) at all time points. Significant anti-
retroviral activities were seen in NP–IDV treated MDM when compared to
soluble IDV sulfate (#P<0.05). The infected MDM were determined by HIV-1
p24 antigen immunostaining (B, red). A large proportion of HIV-1 p24 positive
cells was present in untreated cultures. In contrast, NP–IDV treated cultures
showed a dramatic reduction in HIV-1 p24 expression. The soluble IDV sulfate
treatment reduced numbers of HIV-1 p24 positive cells, however, MGC were
still seen. Original magnification ×200. MDM viability was tested by the
mitochondrial MTT assay following exposure to soluble IDV sulfate and NP–
IDV treated and HIV-1 infected MDM (C). HIV-1 infection caused a significant
loss of MDM viability when compared to uninfected cells and infected cultures
treated with soluble IDV sulfate and NP–IDV. Both drugs did not induce MDM
toxicity (*P<0.05).
154 H. Dou et al. / Virology 358 (2007) 148–158One “real” advantage of the current therapeutic strategy rests
in its simplicity. It seemingly reverses a natural pathogenic
mechanism for viral infection. The underlying principle for our
study was based on the specific delivery of antiviral agents to
the site of active viral replication. Indeed, monocytes and
macrophages are major target cells for HIV-1, serve as vehicles
for microbial dissemination throughout the body, and interact
with CD4+ T lymphocytes within a wide range of tissues during
the course of an immune response (Kotwal, 1997; Weyand and
Goronzy, 1992). Simply put, where drug is delivered by
macrophages is where viral replication occurs, thus readily
inhibiting replication. This is especially relevant as macro-
phages can enter into tissues that limit entry of many anti-
retroviral drugs, which includes the central nervous system. In
regards to disease, HIV-1 infected macrophages enter the brain
early in the infection and play a crucial role in the pathogenesis
and progression of HIV-1 associated cognitive impairments
(Stoll and Jander, 1999; Zenger et al., 1997). Agents capable of
controlling HIV-1 infection within MP, as well as halting the
progression of cellular immune dysfunctions, may thus have an
important place in the management of HIV disease (Verani et al.,
2005).
IDV, an ART protease inhibitor, prevents the production of
infectious virus by blocking the virus-encoded aspartyl
protease (Boffito et al., 2003; Miller et al., 2004; Perno,
1998). Several HIV-1 protease inhibitors, now in widespread
clinical use, are strong inhibitors of virus when used in
combination with nucleoside and non-nucleoside reverse
transcriptase inhibitors (Delaugerre et al., 2005a; Fellay et al.,
2001; Pezzotti et al., 1999; Prejdova et al., 2004; Stein et al.,
1996). NP–IDV delivery by macrophages offers an opportunity
to optimize antiviral therapy by limiting dosing regimens and
improving delivery to sites where virus replication remains
most active.
Prior studies demonstrate that NP uptake into cells are
dependent upon the particle size (Dailey et al., 2003; Griese and
Reinhardt, 1998; Singh et al., 2003). The results of this study,
however, showed that NP up to 8.4 μm did not influence MDM
uptake. Indeed, electron microscopic analyses indicated that
NP–IDV likely underwent endocytosis by MDM thereby
forming drug-laden vacuoles. The ability of macrophages to
engulf NP opens new possibilities for drug delivery in disease. In
addition to the size of the individual particles, the concentration
of drug secreted by the macrophage was above the therapeutic
dose and below the toxic dose, critically important components
of antiviral therapeutic efficiency (Dou et al., in press). Cell
uptake of NP–IDV was dependent on the concentration of the
NP in the medium and the incubation time (data not show). Up to
74.4% of NP–IDV were concentrated in macrophages within
24 h and consistent intracellular concentrations were maintained
for days. Alkaline pH limits solubility of NP–IDVand enhances
physical stability. Following drug ingestion by macrophages,
decreasing phagosomal pH enhances drug release. Two very
distinct physico-chemical steps are involved in the release of
intracellular NP–IDV, including the initial dissolution of the NP
in the cell and subsequent diffusion of the released IDV into the
extracellular media.
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phages and improved anti-retroviral activities as compared to
solution of IDV. NP–IDV delivered through macrophages offers
a unique opportunity for selective drug delivery to more
contained reservoirs of virus, while limiting toxicity and complex
drug scheduling, as well as, being suitable for cells that already
contain pro-viral DNA (H. Dou et al., in press). Treatment of
HIV-1 associated disease requires life long therapy. In contrast to
multiple daily dose regimens, NP–IDV-BMM has improved
efficacy. If similar approaches can be employed in combination
therapy, a likely possibility, such NP systems could affect drug
usage in the developing world. In this regard, we are now
planning a nanoformulation trial for HIV-1 infected patients.
Subjects would be recruits who have failed conventional therapy
or in whom oral administration cannot be administered or
absorbed adequately. For this a “modified” leukophoresis system
for monocyte-enriched PBMC fractionation can be done at the
time of drug administration and during the cell separation
procedure. This would limit cell manipulations. The numbers of
autologous monocytes required for treatment in humans still
awaits cell-dose response measurements and pre-clinical drug
biodistributions. All together, we theorize that NP–IDV delivery
to macrophages would significantly enhance bioavailability, as
well as, its passage through the blood–brain barrier. Such results,
if successfully translated, offers many new possibilities for
greater access and clinical efficacy of ART in an era when
infections continue to progress and evolve, while limited access
to ART is an ever-present reality.
Materials and methods
NP preparation and characterization
IDV suspensions were prepared by high-pressure homoge-
nization. The surfactant coating of the IDV crystals were
comprised of Lipoid E80, an egg phosphatide mixture of
phosphatidylcholine, phosphatidylethanoloamine, and the hy-
drolyzed lyso (single aliphatic chain). Lipoid E80, 1.2% w/v
coated the particles. The nanosuspension was formulated at an
alkaline pH at 8.5. 1.2 g IDV free-base was added to the
phospholipid dispersion and a pre-suspension prepared using an
Ultraturrax rotor-stator mixer for 4 min to reduce particle size.
An isotonic buffer solution was made by dissolving 1.8 g sodium
chloride and 0.28 g sodium phosphate dibasic in 200 mL of
water. The pre-suspension was homogenized at 15,000 psi for 40
passes. NP drug crystals were prepared from free-base and
stabilized by phospholipid layers. Particle size was optimized to
minimize dissolution before and during macrophage uptake and
measured using light scattering and suspension stability assays
and assessed by stress and short-term stability tests. Optimiza-
tion for temperature and homogenization cycles was achieved
and the resultingNPs formed into concentrations of 10− 2 M. The
lipid based particles were comprised of the crystalline IDV free-
base coated and stabilized by phospholipids, and tagged-lipids.
The phospholipids maintained particle stability. At the pH that
the particles were used they are negatively charged. rDHPE
(Invitrogen, Carlsbad, CA) was used to label NP–IDV, whichappeared as red fluorescence. The rDHPE-labeled NP–IDV
(rDHPE–NP–IDV) could be visualized under fluorescence
microscopy by red fluorescence with a peak fluorescence
emission of approximately 595 nm.
Human monocyte isolation, cultivation and viral infection
Human monocytes were obtained from leukopaks of HIV-1,
-2 and hepatitis B seronegative donors and purified by coun-
tercurrent centrifugal elutriation. Cells were cultured with
DMEM with 10% heat-inactivated pooled human serum, 1%
glutamine, and 10 mg/ml ciprofloxacin (Sigma Chemical Co),
and 1000 U/ml highly purified recombinant human macrophage
colony stimulating factor (MCSF; a generous gift from Wyeth
Inc., Cambridge, MA). Seven days after plating, MDM were
infected with HIV-1ADA at a multiplicity of infection (MOI) of
0.1 infectious viral particles/target cell (Gendelman et al.,
1988). Culture medium was half-exchanged every 2–3 days.
All viral stocks were tested and found to be free of mycoplasma
and endotoxin contamination (Gen-Probe II; Gen-Probe, San
Diego, CA).
AFM
For AFM, 5 μg/ml NP–IDV in PBS was deposited onto
freshly cleaved mica that was glued to glass microscope slides.
The NP were adsorbed to the mica for 2 min at room
temperature. After incubation, the sample was gently washed
with distilled water to remove non-adsorbed particles and dried
under argon flow. Glass slides with NP–IDV were mounted on
the scanner of a stand-alone MFP-3D AF microscope (Asylum
Research, Santa Barbara, CA). Images were taken in alternate
contact with standard silicon nitride cantilever for air. Height,
amplitude, and phase images were recorded simultaneously.
Typical scan sizes were 1–10 μm at a resolution of 512×512
data points. The analysis of the images was performed with
Femtoscan software. A dimension 3100 model AF microscope
(Veeco, Santa Barbara, CA) determined the morphology of the
NP at room temperature. The system included single-beam
silicon cantilevers (Olympus OMCL-AC160TS-W2 Tapping
Mode) with spring constants of ∼45 N/m and resonant
frequencies of ∼300 kHz. All topographs were recorded in
tapping mode. The resulting images have been flattened and
plane fitted.
Electron microscopy
To determine the shape and size of NP–IDV, nanosuspen-
sions were examined with a Hitachi S-3000N scanning electron
microscope. NP shape and structural integrity were examined in
ultra-thin sections. For TEM, HIV-1ADA infected MDM were
exposed to NP at 5×10− 4 M for 12 h and followed for 10 days.
Cells were rinsed with PBS, fixed with 2.5% glutaraldehyde for
30 min, post-fixed with 1% osmic acid, dehydrated in graded
ethanol solutions, and embedded in Epon 812 mixture. Thin
sections were cut and stained with 2% urinal acetate and
examined under a Hitachi H7500.
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MDM were exposed to HIV-1ADA for 4 h following fresh
media change. Infected cultures were post-treated with NP–
IDV or IDV (5×10− 4 M) on day 1. Immunohistology assays
were performed at day 3, 5 and 7 post-infection.
Comparison of anti-retroviral activities in HIV-1 infected
MDM were performed for soluble IDV sulfate or NP–IDV at
5×10− 4 M (10 times solubility level). MDM were treated with
single supplement of soluble IDV sulfate or NP–IDV for 12 h
and then fresh media change. After 5 days, treated MDM were
exposed to HIV-1ADA and assayed at post-infection days 3, 5
and 7 for levels of viral infection and cytopathology (see below).
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
(MTT) assay
MTT reduction was measured in MDM, with or without,
free-base IDV sulfate or NP–IDVat a concentration of 1×10− 6
to 1×10− 15 M. The assay is based on the ability of active
mitochondrial dehydrogenase to convert dissolved MTT to
water-insoluble purple formazan crystals. To each MDM-
containing well in a 24 well plate was added 500 μl of MTT
solution [5 mg/ml solution in 10% fetal bovine serum (FBS) in
phosphate buffered saline (PBS)] and incubated for 4 h at
37 °C. At the end of the incubation period, the media was
replaced with 500 μl of dimethyl sphingosine (DMS) and the
samples were left for 15 min at room temperature. A 100 μl
sample of lysate from each well was transferred to a 96-well
plate, and the ELISA reader was set at 490 nm.
Reverse transcriptase (RT) assay
Progeny virion production was measured by analysis of RT
activity in triplicate samples of MDM culture supernatants.
Briefly, 10 mL of supernatant was added to a reaction mixture of
0.05% Nonidet P-40, 10 mg/ml poly (A), 0.25 mg/ml oligo(dT),
5 mM DTT, 150 mM KCl, 15 mM MgCl2, and [3H]dTT in
Tris–HCl buffer (pH 7.9), and incubated for 24 h at 37 °C.
Radiolabeled nucleotides were precipitated with 10% cold TCA
and 95% ethanol in an automatic cell harvester on paper filters.
Radioactivity was estimated using liquid scintillation spectros-
copy (Kalter et al., 1991).
Reverse-phase high performance liquid chromatography
(RP-HPLC)
For IDV determinations, macrophages were harvested and
centrifuged at 1,400×g for 10min at 25 °C in 50%methanol. The
pellet was homogenized with a hand-held electric pestle and
then centrifuged again as above. The supernatant was
withdrawn, evaporated to dryness under a nitrogen stream,
then reconstituted with mobile phase and placed in auto-
sampler vials for injection. The mobile phase contained 10 mM
ammonium dihydrophosphate and 1 mM 1-heptanesulfonic
acid in 18-Ω (ohm) water adjusted to pH 4.8 with phosphoric
acid. A total of 650 ml of aqueous phase was combined with350 ml of 100% acetonitrile and then filtered and degassed. The
flow rate was 0.6 ml/min and the detector was set at 210 nm.
IDV standards (0.01 M) were diluted to obtain a 50–1000 ng/
ml standard curve. Samples were diluted appropriately to fit
within the range of the standard curve. The HPLC apparatus
included a pump (LC-10ATvp); system controller (SCL-
10AVP), refrigerated auto-sampler (SIL-10ADvp), degasser
(DGU-14A), a low-flow gradient mixer (LC-8A), and a UV-
Visual detector (SPD-10Avp). All were from Shimadzu, Corp,
Columbia, MD. Samples were run through a C18 pre-column
and a Jupiter C4 reverse-phase [150×3.9 mm (I.D.)] with 5 mm
particle size packing (Phenomenex, Torrance, CA). Peak area
from samples and standards were integrated using EZ-Start
chromatography software (Shimadzu) on a Dell computer. The
injection volume was 20 mL and all samples were analyzed in
triplicate and averaged.
Immunohistochemistry
Cells were fixed in 4% paraformaldehyde for 1 h. HIV-1
infected MDM were tested for HIV-1 p24 antigen expression
with a p24 specific monoclonal antibody (clone Kal-1, Dako
Carpinteria, CA). An antibody that specifically labels macro-
phages, HAM56 (Dako), was used to assess purity of human
macrophages within cultures. Cell nuclei were detected by 4′6-
diamidino-2-phenyl-indole, dihydrochloride (DAPI) (Molecular
Probes, Eugene, OR). Triple-immunofluorescence staining was
carried out using Alexa Fluor®-conjugated secondary antibody
(Molecular Probes).
Statistical analyses
The data were analyzed and comparisons performed by two-
tailed unpaired t test. P values of <0.05 were deemed significant.
Analyses were performed with GraphPad Prism version 4.0
(GraphPad Software, San Diego, CA) for Macintosh.
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